All Invest Securities Flash Update to the Equity Research Coverage of ABL Diagnostics (For Professional Investors)

Strong Buy reiterated with a €8.37 target price following the 21 January 2026 Flash; last close on 22 January 2026: ...
Morningstar

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger The contemplated transaction remains subject to due ...
Investing

ProPhase Labs and ABL announce reverse merger plans

UNIONDALE, NY - ProPhase Labs, Inc. (NASDAQ:PRPH) and European biotechnology group Advanced Biological Laboratories S.A. (ABL) announced Friday they have entered into a non-binding Letter of Intent ...
Investing

ProPhase Labs stock soars after announcing reverse merger with ABL

Investing.com -- ProPhase Labs Inc (NASDAQ:PRPH) stock surged 75.2% in premarket trading Friday after the company announced a non-binding letter of intent for a reverse merger with Advanced Biological ...
Business Wire

ABL DIAGNOSTICS, Key Player in the Diagnosis of Infectious Diseases by Genotyping, Presents Its Development Plan to the Financial Community

PARIS--(BUSINESS WIRE)--Regulatory News: ABL DIAGNOSTICS (Euronext Paris, FR001400AHX6, ABLD) today presents its ABLDX 2027 medium-term development plan to the financial community. Formed from the end ...
The Globe and Mail

ProPhase Labs Announces Proposed Reverse Merger with ABL

Prophase Labs ( (PRPH)) just unveiled an update. ProPhase Labs, Inc. announced that it has entered into a non-binding letter of intent for a proposed reverse merger with Advanced Biological ...
Seeking Alpha

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger

The contemplated transaction remains subject to due diligence, definitive agreements, regulatory approvals and Nasdaq listing requirements; no change to ABL S.A.’s control over ABL Diagnostics at this ...